Abstract:Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer treatment in the last decade, giving unprecedented results against hematological malignancies. All approved CAR T-cell products, as well as many being assessed in clinical trials, are generated using viral vectors to deploy the exogenous genetic material into T-cells. Viral vectors have a long-standing clinical history in gene delivery, and thus underwent iterations of optimization to improve their efficiency and safety. Nonetheless, their capacity to integrate semi-randomly into the host genome makes them potentially oncogenic via insertional mutagenesis and dysregulation of key cellular genes. Secondary cancers following CAR T-cell administration appear to be a rare adverse event. However several cases documented in the last few years put the spotlight on this issue, which might have been underestimated so far, given the relatively recent deployment of CAR T-cell therapies. Furthermore, the initial successes obtained in hematological malignancies have not yet been replicated in solid tumors. It is now clear that further enhancements are needed to allow CAR T-cells to increase long-term persistence, overcome exhaustion and cope with the immunosuppressive tumor microenvironment. To this aim, a variety of genomic engineering strategies are under evaluation, most relying on CRISPR/Cas9 or other gene editing technologies. These approaches are liable to introduce unintended, irreversible genomic alterations in the product cells. In the first part of this review, we will discuss the viral and non-viral approaches used for the generation of CAR T-cells, whereas in the second part we will focus on gene editing and non-gene editing T-cell engineering, with particular regard to advantages, limitations, and safety. Finally, we will critically analyze the different gene deployment and genomic engineering combinations, delineating strategies with a superior safety profile for the production of next-generation CAR T-cell.

Regulatory Considerations for Genome-Edited T-cell Therapies

Genome Editing in Engineered T Cells for Cancer Immunotherapy

Genome-editing Technologies for Gene and Cell Therapy

Engineering strategies to safely drive CAR T-cells into the future

Genetic engineering of T cells for immunotherapy

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future

Identification of core techniques that enhance genome editing of human T cells expressing synthetic antigen receptors

Building Potent Chimeric Antigen Receptor T Cells with CRISPR Genome Editing

Applications of CRISPR technologies to the development of gene and cell therapy

Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects

Genome Editing Techniques and Their Therapeutic Applications

A new age of precision gene therapy

Recent Therapeutic Gene Editing Applications to Genetic Disorders

The History, Use, and Challenges of Therapeutic Somatic Cell and Germline Gene Editing

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells

Application of Genome Editing Techniques in Immunology

Engineering transcriptional regulation for cell-based therapies

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy